FLGR242
FLGR242 is a seller name for a claimed follistatin-derived, albumin-binding construct. Sellers publish partial specifications, but the cited evidence does not establish a complete molecular identity, compound-specific pharmacology, or benefit in animals or humans.
seller-described follistatin-albumin construct
- Complete construct not independently disclosed
- About 40 kDa and below-20 nM albumin affinity are seller claims
- The 19-day persistence figure is a seller claim
- No independent administration study appears in the cited public records
What exactly is FLGR242?
Sellers do not provide a reproducible complete identity. One seller describes a follistatin fragment, glycine-serine linker, and albumin-binding element, but does not supply the complete construct and independent analytical package needed to establish identity.
- Sequence: complete termini, linker, albumin-binding element, modifications, and glycosylation state.
- Structure: independent intact mass, peptide mapping, disulfide and fold characterization, and aggregation.
- Function: target, off-target, albumin-binding, and myostatin or activin bioactivity on the named material.
- Parenteral quality: content, sterility, endotoxin, particles, stability, and container-level release data.
Seller page · partial construct claims
Commercial product page
BioLongevity Research.
The seller describes a follistatin fragment connected through a glycine-serine linker to an albumin-binding element, about 40 kDa mass, below-20 nM albumin affinity, and a 10 mg lyophilized presentation. It does not publish an independent complete sequence, analytical map, or validation study.
- Study design
- Seller-authored product description
- Funding
- Seller
Useful only for documenting what is marketed.
Read the original sourcePubMed · no independent FLGR242 paper
Literature record set
PubMed records.
PubMed contained no FLGR242 characterization, binding, animal, pharmacokinetic, safety, or efficacy paper under the exact name.
- Study design
- Exact-name and spacing-variant coverage
US20260008820A1 · generic platform, no FLGR242
Patent application
US Patent Application US20260008820A1.
The application describes a broad glycopeptide albumin-binding platform. The patent does not name FLGR242, disclose an FLGR242 sequence, identify an FLGR242 test article, or report FLGR242 pharmacokinetics.
- Study design
- Applicant-written platform disclosure
It cannot fill the compound-specific identity gap.
Read the original sourceHas FLGR242 been administered in animals or people?
The cited public records contain no independent FLGR242 animal or human administration study. They provide no studied dose, route, interval, clinical outcome, or adverse-event denominator.
Does the 40 kDa figure prove identity?
An approximate seller-listed mass cannot reveal the full sequence, modification state, correct fold, aggregates, binding, or functional potency.
Seller page · partial construct claims
Commercial product page
BioLongevity Research.
The seller describes a follistatin fragment connected through a glycine-serine linker to an albumin-binding element, about 40 kDa mass, below-20 nM albumin affinity, and a 10 mg lyophilized presentation. It does not publish an independent complete sequence, analytical map, or validation study.
- Study design
- Seller-authored product description
- Funding
- Seller
Useful only for documenting what is marketed.
Read the original sourcePubMed · no independent FLGR242 paper
Literature record set
PubMed records.
PubMed contained no FLGR242 characterization, binding, animal, pharmacokinetic, safety, or efficacy paper under the exact name.
- Study design
- Exact-name and spacing-variant coverage
ClinicalTrials.gov · no FLGR242 human study
Registry record set
ClinicalTrials.gov records.
ClinicalTrials.gov contained no registered FLGR242 human study under the exact name or spacing variant.
- Study design
- Exact-name registry coverage
Does FLGR242 inhibit myostatin?
No FLGR242-specific myostatin inhibition has been demonstrated. The cited patent describes a generic albumin-binding platform and does not name or test FLGR242; results for natural follistatin, FST315, FST288, or AAV-FS344 do not apply to it.
US20260008820A1 · generic platform, no FLGR242
Patent application
US Patent Application US20260008820A1.
The application describes a broad glycopeptide albumin-binding platform. The patent does not name FLGR242, disclose an FLGR242 sequence, identify an FLGR242 test article, or report FLGR242 pharmacokinetics.
- Study design
- Applicant-written platform disclosure
It cannot fill the compound-specific identity gap.
Read the original sourceSeller page · partial construct claims
Commercial product page
BioLongevity Research.
The seller describes a follistatin fragment connected through a glycine-serine linker to an albumin-binding element, about 40 kDa mass, below-20 nM albumin affinity, and a 10 mg lyophilized presentation. It does not publish an independent complete sequence, analytical map, or validation study.
- Study design
- Seller-authored product description
- Funding
- Seller
Useful only for documenting what is marketed.
Read the original sourcePubMed · no independent FLGR242 paper
Literature record set
PubMed records.
PubMed contained no FLGR242 characterization, binding, animal, pharmacokinetic, safety, or efficacy paper under the exact name.
- Study design
- Exact-name and spacing-variant coverage
What is known about safety?
The cited public records contain no compound-specific safety data. Identity, exposure, immune response, broad activin-family effects, fertility, vascular and tumor biology, pregnancy, interactions, and sterile-product quality are unresolved.
Does a lyophilized vial establish an injectable route?
A lyophilized vial and bacteriostatic-water presentation do not establish a studied route, dose, sterility, or injection safety.
Seller page · 19-day persistence claim
Commercial product page
BioLongevity Labs.
The seller markets 2 mg FLGR242 in a B-vitamin blend and claims serum persistence of about 19 days. It provides no compound-specific concentration-time curve or independent pharmacokinetic report. A vial and bacteriostatic-water presentation do not establish a studied route.
- Study design
- Seller-authored product description
- Funding
- Seller
PubMed · no independent FLGR242 paper
Literature record set
PubMed records.
PubMed contained no FLGR242 characterization, binding, animal, pharmacokinetic, safety, or efficacy paper under the exact name.
- Study design
- Exact-name and spacing-variant coverage
ClinicalTrials.gov · no FLGR242 human study
Registry record set
ClinicalTrials.gov records.
ClinicalTrials.gov contained no registered FLGR242 human study under the exact name or spacing variant.
- Study design
- Exact-name registry coverage
Seller page · partial construct claims
Commercial product page
BioLongevity Research.
The seller describes a follistatin fragment connected through a glycine-serine linker to an albumin-binding element, about 40 kDa mass, below-20 nM albumin affinity, and a 10 mg lyophilized presentation. It does not publish an independent complete sequence, analytical map, or validation study.
- Study design
- Seller-authored product description
- Funding
- Seller
Useful only for documenting what is marketed.
Read the original sourceDoes FLGR242 have a 19-day half-life or an approval?
The cited U.S. records contain no compound-specific pharmacokinetic curve or exact-name approval entry. The 19-day figure is a seller claim. WADA’s S0 category prohibits non-approved substances, and the claimed myostatin-modulating action may also fall under S4.3 if confirmed.
Seller page · 19-day persistence claim
Commercial product page
BioLongevity Labs.
The seller markets 2 mg FLGR242 in a B-vitamin blend and claims serum persistence of about 19 days. It provides no compound-specific concentration-time curve or independent pharmacokinetic report. A vial and bacteriostatic-water presentation do not establish a studied route.
- Study design
- Seller-authored product description
- Funding
- Seller
openFDA · no exact-name approval record
Regulatory database record set
openFDA Drugs@FDA records.
The cited U.S. approval records contain no exact-name entry for FLGR242. This does not establish approval status in every country or under every possible spelling.
- Study design
- Exact-name U.S. approval coverage
WADA 2026 · status depends on actual identity
Sports rule
World Anti-Doping Agency, effective 1 January 2026.
S0 prohibits non-approved pharmacological substances, and S4.3 prohibits myostatin-function modifiers. Which provision applies to FLGR242 depends on establishing what the product actually is and does.
- Study design
- Binding sport rule for covered athletes
Studies and sources
PubMed · no independent FLGR242 paper
Literature record set
PubMed records.
PubMed contained no FLGR242 characterization, binding, animal, pharmacokinetic, safety, or efficacy paper under the exact name.
- Study design
- Exact-name and spacing-variant coverage
ClinicalTrials.gov · no FLGR242 human study
Registry record set
ClinicalTrials.gov records.
ClinicalTrials.gov contained no registered FLGR242 human study under the exact name or spacing variant.
- Study design
- Exact-name registry coverage
US20260008820A1 · generic platform, no FLGR242
Patent application
US Patent Application US20260008820A1.
The application describes a broad glycopeptide albumin-binding platform. The patent does not name FLGR242, disclose an FLGR242 sequence, identify an FLGR242 test article, or report FLGR242 pharmacokinetics.
- Study design
- Applicant-written platform disclosure
It cannot fill the compound-specific identity gap.
Read the original sourceSeller page · partial construct claims
Commercial product page
BioLongevity Research.
The seller describes a follistatin fragment connected through a glycine-serine linker to an albumin-binding element, about 40 kDa mass, below-20 nM albumin affinity, and a 10 mg lyophilized presentation. It does not publish an independent complete sequence, analytical map, or validation study.
- Study design
- Seller-authored product description
- Funding
- Seller
Useful only for documenting what is marketed.
Read the original sourceSeller page · 19-day persistence claim
Commercial product page
BioLongevity Labs.
The seller markets 2 mg FLGR242 in a B-vitamin blend and claims serum persistence of about 19 days. It provides no compound-specific concentration-time curve or independent pharmacokinetic report. A vial and bacteriostatic-water presentation do not establish a studied route.
- Study design
- Seller-authored product description
- Funding
- Seller
openFDA · no exact-name approval record
Regulatory database record set
openFDA Drugs@FDA records.
The cited U.S. approval records contain no exact-name entry for FLGR242. This does not establish approval status in every country or under every possible spelling.
- Study design
- Exact-name U.S. approval coverage
WADA 2026 · status depends on actual identity
Sports rule
World Anti-Doping Agency, effective 1 January 2026.
S0 prohibits non-approved pharmacological substances, and S4.3 prohibits myostatin-function modifiers. Which provision applies to FLGR242 depends on establishing what the product actually is and does.
- Study design
- Binding sport rule for covered athletes
Why is FLGR242 in F tier?
The F grade reflects an unresolved molecular identity and the absence of an independent administration study in the cited public records. Seller specifications do not provide a complete sequence, analytical identity, pharmacology, or pharmacokinetics.